In short
Clinical trials are investigating Ibrexafungerp in people with invasive candidiasis and candidemia, which are serious fungal infections in the blood or body. These studies look at whether treatment is safe and effective after initial intravenous therapy, and compare it with other standard oral treatments.
Key points
- Ibrexafungerp is being studied in clinical trials for serious Candida infections, especially invasive candidiasis and candidemia. The main trial in the source data is a Phase 3 study with 240 participants. It compares intravenous echinocandin followed by oral Ibrexafungerp with intravenous echinocandin followed by oral fluconazole. The trial is designed to see whether Ibrexafungerp is non-inferior, meaning not worse than, the comparison treatment by more than a small amount. The main outcomes are all-cause mortality at Day 30 and successful global response at the end of treatment. The listed trial is completed.
Trial overview
The source data includes one clinical trial of Ibrexafungerp, NCT05178862, which studied people with invasive candidiasis and candidemia.
This was an interventional study, which means the researchers gave study treatments and then measured the results.
The trial asked whether treatment with an intravenous echinocandin followed by oral Ibrexafungerp could work as well as intravenous echinocandin followed by oral fluconazole.
Who the trial is for
The study focused on people with serious Candida infections, specifically invasive candidiasis or candidemia.
Candidemia means Candida infection in the blood, and invasive candidiasis means the infection has spread inside the body.
The source data does not give more detailed age or other entry rules, so only the listed condition can be confirmed here.
Treatments being compared
The trial compared two treatment paths after the first intravenous antifungal medicine.
One path used an intravenous echinocandin first, then oral Ibrexafungerp.
The other path used an intravenous echinocandin first, then oral fluconazole, or best available therapy in some settings.
The source data also lists several study drugs and placebos used in the trial design, including placebo for Ibrexafungerp and placebo for fluconazole.
Study phase and design
NCT05178862 was a Phase 3 trial.
Phase 3 studies usually test a treatment in a larger group of people and compare it with standard care or another active treatment.
The planned enrollment was 240 participants.
The brief summary says the goal was to show that the Ibrexafungerp treatment path was non-inferior to the fluconazole path.
Main outcomes being measured
The main outcome was all-cause mortality at Day 30 in the ITT population.
All-cause mortality means death from any cause during the study period, and ITT population means the analysis includes the patients assigned to treatment.
The trial also measured the percentage of people with successful global response at the end of treatment.
This second outcome was noted as being for EU only in the source data.
What the completed status means
The study status is listed as Completed, which means the trial has finished collecting its planned data.
Because the trial is completed, the source data describes the study plan and outcomes, but not the final results.